Acuta Capital Partners, LLC Atara Biotherapeutics, Inc. Transaction History
Acuta Capital Partners, LLC
- $53.1 Million
- Q3 2025
A detailed history of Acuta Capital Partners, LLC transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 55,000 shares of ATRA stock, worth $756,800. This represents 0.19% of its overall portfolio holdings.
Number of Shares
55,000Holding current value
$756,800% of portfolio
0.19%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ATRA
# of Institutions
6Shares Held
2.89MCall Options Held
0Put Options Held
0-
Kpcb Xv Associates, LLC1.88MShares$25.8 Million19.79% of portfolio
-
Antipodean Advisors LLC New York, NY1MShares$13.8 Million8.12% of portfolio
-
American Portfolios Advisors Holbrook, NY4.5KShares$61,9200.0% of portfolio
-
Wipfli Financial Advisors Llc,3.08KShares$42,3670.0% of portfolio
-
Act Capital Management, LLC Wayne, PA900Shares$12,3840.0% of portfolio
About Atara Biotherapeutics, Inc.
- Ticker ATRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,362,304
- Market Cap $1.3B
- Description
- Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...